ILB 2102
Alternative Names: ILB-2102Latest Information Update: 26 Sep 2022
At a glance
- Originator Innolake Biopharm
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Autoimmune disorders
Most Recent Events
- 20 Sep 2022 ILB 2102 is available for licensing as of 20 Sep 2022. https://www.innolakebio.com/PartnershipStrategy/index.aspx
- 20 Sep 2022 Phase-II clinical trials in Autoimmune disorders in USA, prior to September 2022 (Innolake Biopharm pipeline, September 2022).
- 20 Sep 2022 Preclinical development in Autoimmune disorders in China, prior to September 2022 (Innolake Biopharm pipeline, September 2022).